Corlanor (IVabradine HCl) Patent Expiration, LOE Window & CMS Spending
Corlanor (IVabradine HCl) by Amgen: FDA Orange Book core substance LOE 2027-06-12, 6 AB generics, $59.5M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amgen |
| FDA Application & Pathway | N206143 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2027-06-12 |
| Last Listed Patent or Exclusivity Date | 2027-06-12 |
| Orange Book Patents (*PED Extensions) | 8 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 6 |
| 2024 CMS Total Public Spend | $59.5M |
| 2024 Medicare Part D Spend | $40.0M |
| 2024 Medicaid Spend | $19.5M |
| Reported Wholesale Price Change (CA SB 17) | 9 WAC filings (max 22.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.